BioMed Research International

Adenomyosis and Myomata: Risks, Problems, and Complications in Diagnosis and Therapy of Adenomyosis and Myomata


Status
Published

1University of Oldenburg, Oldenburg, Germany

2University of Heidelberg, Heidelberg, Germany

3University of Naples Federico II, Napoli, Italy

4University of Nicosia, Nicosia, Cyprus

5University of Frankfurt, Frankfurt, Germany


Adenomyosis and Myomata: Risks, Problems, and Complications in Diagnosis and Therapy of Adenomyosis and Myomata

Description

The therapy of myomata, one of the leading courses of gynaecological disease, is still controversial. The decision whether to follow a medical treatment pathway or to perform surgery is still not completely solved. Even the golden standard concerning the pharmaceutical treatment is not established.

As a special form of the myomata, adenomyomata are even more difficult to treat and more hazardous. Also here the risks and benefits of a surgical treatment compared to a conservative are not defined. As new pharmaceutical products and more sophisticated surgical techniques are arising, clear statements should be made concerning the risks and complications of those treatments.

We invite investigators to submit original research articles and reviews to this special issue. Authors all over the world are invited to submit their papers to the special issue. Submitted papers will undergo a review process.

Potential topics include but are not limited to the following:

  • Medical treatment of adenomyosis
  • Malignancy and myomata
  • Complications in adenomyosis surgery
  • Medical treatments of adenomyosis
  • Awareness of potential surgery risks in myomata
  • Gold standards in myoma therapy
  • In-bag morcellation
  • Uterine rupture after myoma enucleation
  • The risk of electronic power morcellation in myoma surgery
  • Preoperative diagnostics in adenomyosis and myoma
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit